Page last updated: 2024-09-04

ivabradine and aldosterone

ivabradine has been researched along with aldosterone in 2 studies

Compound Research Comparison

Studies (ivabradine)	Trials (ivabradine)	Recent Studies (post-2010) (ivabradine)	Studies (aldosterone)	Trials (aldosterone)	Recent Studies (post-2010) (aldosterone)
1,143	197	833	25,333	1,517	4,169

Protein Interaction Comparison

Protein	Taxonomy	ivabradine (IC50)	aldosterone (IC50)
Mineralocorticoid receptor	Homo sapiens (human)		0.0048
Mineralocorticoid receptor	Rattus norvegicus (Norway rat)		0.043

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Asselin, C; Bouly, M; Brand, G; Busseuil, D; Des Rosiers, C; Gillis, MA; Latour, JG; Leung, TK; Mecteau, M; Rhéaume, E; Roméo, P; Shi, Y; Tardif, JC; Thorin, E	1
Crespo-Leiro, MG; Escobar, C; Esteban-Fernández, A; Farré, N; Garcia, A; Luis-Bonilla, J; Nuñez, J	1

Other Studies

2 other study(ies) available for ivabradine and aldosterone

Article	Year
Heart rate reduction by ivabradine reduces diastolic dysfunction and cardiac fibrosis. Cardiology, 2010, Volume: 117, Issue:3 Topics: Aldosterone; Angiotensin II; Animals; Benzazepines; Cyclic Nucleotide-Gated Cation Channels; Diastole; Echocardiography, Doppler, Pulsed; Fibrosis; Heart Atria; Heart Rate; Heart Ventricles; Hemodynamics; Hypercholesterolemia; Ivabradine; Oxidative Stress; Rabbits; Sinoatrial Node; Ventricular Dysfunction, Left	2010
Individualizing the treatment of patients with heart failure with reduced ejection fraction: a journey from hospitalization to long-term outpatient care. Expert opinion on pharmacotherapy, 2022, Volume: 23, Issue:14 Topics: Aldosterone; Ambulatory Care; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensins; Biphenyl Compounds; Guanylate Cyclase; Heart Failure; Hospitalization; Humans; Ivabradine; Natriuretic Peptides; Potassium; Renin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Valsartan	2022

Article

Year

Heart rate reduction by ivabradine reduces diastolic dysfunction and cardiac fibrosis.

Cardiology, 2010, Volume: 117, Issue:3

Topics: Aldosterone; Angiotensin II; Animals; Benzazepines; Cyclic Nucleotide-Gated Cation Channels; Diastole; Echocardiography, Doppler, Pulsed; Fibrosis; Heart Atria; Heart Rate; Heart Ventricles; Hemodynamics; Hypercholesterolemia; Ivabradine; Oxidative Stress; Rabbits; Sinoatrial Node; Ventricular Dysfunction, Left

2010

Individualizing the treatment of patients with heart failure with reduced ejection fraction: a journey from hospitalization to long-term outpatient care.

Expert opinion on pharmacotherapy, 2022, Volume: 23, Issue:14

Topics: Aldosterone; Ambulatory Care; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensins; Biphenyl Compounds; Guanylate Cyclase; Heart Failure; Hospitalization; Humans; Ivabradine; Natriuretic Peptides; Potassium; Renin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Valsartan

2022